Diklo-f drops Ch. 0.1% 5 ml vial

Description

Composition
Active substance:
1 ml contains: diclofenac sodium 1.0 mg.
Excipients:
Benzalkonium chloride 0.1 mg Disodium edetate 1.0 mg, 15.0 mg of boric acid, 6.0 mg tromethamine, polyoxyl 35 castor oil 20.0 mg, 15.0 mg povidone, sodium hydroxide or hydrochloric acid to pH 7 7 water for injections to 1 mL.
Description:
The clear solution from colorless to pale yellow.
Product form:
0.1% eye drops.
5 ml plastic bottle with screw-drip cap. Each vial-IV together with instructions for use placed in a cardboard box.
Contraindications
Hypersensitivity to the active agent or drug to any auxiliary ingredients entering into the composition of the dosage form of the drug; hypersensitivity to aspirin or other NSAIDs; hemodyscrasia of unknown origin; erosive-ulcerous processes in the gastrointestinal tract in the acute stage.
Carefully.
Epithelial herpetic keratitis (including a history..); diseases causing blood coagulation disorders (including hemophilia, prolonged bleeding, bleeding tendency); elderly age.
No data on the use of the drug in children, therefore use the drug should only be if the expected benefit outweighs the potential risk.
Dosage
1 mg / ml
Indications
Inhibition of miosis during cataract surgery; treatment and prevention of inflammatory processes after surgical interventions on the eyeball; prevention of cystoid macular edema after cataract surgery; treatment of non-infectious conjunctivitis; treatment and prevention of post-traumatic inflammation in penetrating and non-penetrating wounds of the eyeball (in addition to the local antibacterial therapy).
Interaction with other drugs
Not recommended simultaneous application of the drug to diflunizalom (since it may develop bleeding from the gastrointestinal tract) and other NSAIDs, including aspirin at high doses (3 g or more per day), sulfonylureas, methotrexate.
Application together with lithium therapy, digitoxin, indirect anticoagulants leading to their strengthening effect.
If necessary, can be used concomitantly with other eye drops, including those containing steroids. The break between applications should be no less than 5 minutes to prevent leaching of the active ingredients by subsequent doses.
Overdose
No data on drug overdose.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug (NSAID).
Pharmacodynamics:
Diclofenac has antiinflammatory, analgesic and antipyretic action. The mechanism of action caused by non-selective inhibition of cyclooxygenase 1 and 2, which leads to suppression of the synthesis of prostaglandins in inflammation.
When used as a 0.1% solution of diclofenac eye drops reduce eye inflammation resulting from infection, injury or surgery; reduces miosis during surgery, reduces the synthesis of prostaglandins in the anterior chamber of moisture.
Pharmacokinetics:
The drug penetrates well into various eye tissues with the exception of the lens. C max occurs within 30 minutes, the maximum concentration observed in the anterior chamber of moisture. There is a systemic absorption. However, the concentration of drug achieved in the blood well below the limit of detection and has no clinical significance.
Pregnancy and breast-feeding
No data on the use of the drug during pregnancy and lactation. When using NSAIDs in the III trimester of pregnancy may increase the risk of fetal circulation. The use in pregnant women and nursing mothers can only be prescribed by a doctor, if the expected therapeutic effect is greater than the risk of possible side effects.
Conditions of supply of pharmacies
On prescription.
side effects
In rare cases, during use of the preparation were noted following undesirable side effects: burning eyes, blurred vision (immediately after instillation); corneal opacity (cataract), iritis.
Allergic reactions: itchy eyes, redness, angioneurotic edema of the face, fever, chills, photosensitivity, cutaneous rash (primarily erythematous, urticaria), erythema multiforme; nausea, vomiting.
special instructions
Patients who use contact lenses must apply the drug
Diklo-F® only when taken with the lens and can put them in 15 minutes after instillation of the preparation.
After removing the burying of contact lenses produced in 5 min.
The bottle must be closed after each use. Do not touch the pipette tip to the eye.
In the period of treatment should refrain from activities potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
At a temperature of not higher than 30 ° C, protected from light. Do not freeze. Keep out of the reach of children.
Dosing and Administration
Locally. For inhibiting intra-operative miosis drug is instilled into the conjunctival sac for 2 hours in 30 minute intervals (4 times) before operation.
For the prevention of cystic macular edema drug instilled 1 drop of 3 – 4 times daily for 2 weeks after surgery.
Other indications: 1 drop of 3 – 4 times a day depending on the severity of the condition. The course of treatment can last from 1 to 2 weeks.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist